Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases

Reactivation of overt or occult HBV infection (HBVr) is a well-known, potentially life-threatening event which can occur during the course of immunosuppressive treatments. Although it has been described mainly in subjects receiving therapy for oncological or hematological diseases, the increasing us...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lorenzo Onorato, Mariantonietta Pisaturo, Clarissa Camaioni, Pierantonio Grimaldi, Alessio Vinicio Codella, Federica Calò, Nicola Coppola
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	HBV infection HBV reactivation rheumatological diseases gastrointestinal diseases neurological diseases dermatological diseases Medicine R
Acceso en línea:	https://doaj.org/article/ba33ec8552d54797824e2c1386376070
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ba33ec8552d54797824e2c1386376070
record_format	dspace
spelling	oai:doaj.org-article:ba33ec8552d54797824e2c13863760702021-11-11T17:48:26ZRisk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases10.3390/jcm102152012077-0383https://doaj.org/article/ba33ec8552d54797824e2c13863760702021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/5201https://doaj.org/toc/2077-0383Reactivation of overt or occult HBV infection (HBVr) is a well-known, potentially life-threatening event which can occur during the course of immunosuppressive treatments. Although it has been described mainly in subjects receiving therapy for oncological or hematological diseases, the increasing use of immunosuppressant agents in non-oncological patients observed in recent years has raised concerns about the risk of reactivation in several other settings. However, few data can be found in the literature on the occurrence of HBVr in these populations, and few clear recommendations on its management have been defined. The present paper was written to provide an overview of the risk of HBV reactivation in non-neoplastic patients treated with immunosuppressive drugs, particularly for rheumatological, gastrointestinal, dermatological and neurological diseases, and for COVID-19 patients receiving immunomodulating agents; and to discuss the potential strategies for prevention and treatment of HBVr in these settings.Lorenzo OnoratoMariantonietta PisaturoClarissa CamaioniPierantonio GrimaldiAlessio Vinicio CodellaFederica CalòNicola CoppolaMDPI AGarticleHBV infectionHBV reactivationrheumatological diseasesgastrointestinal diseasesneurological diseasesdermatological diseasesMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5201, p 5201 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	HBV infection HBV reactivation rheumatological diseases gastrointestinal diseases neurological diseases dermatological diseases Medicine R
spellingShingle	HBV infection HBV reactivation rheumatological diseases gastrointestinal diseases neurological diseases dermatological diseases Medicine R Lorenzo Onorato Mariantonietta Pisaturo Clarissa Camaioni Pierantonio Grimaldi Alessio Vinicio Codella Federica Calò Nicola Coppola Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases
description	Reactivation of overt or occult HBV infection (HBVr) is a well-known, potentially life-threatening event which can occur during the course of immunosuppressive treatments. Although it has been described mainly in subjects receiving therapy for oncological or hematological diseases, the increasing use of immunosuppressant agents in non-oncological patients observed in recent years has raised concerns about the risk of reactivation in several other settings. However, few data can be found in the literature on the occurrence of HBVr in these populations, and few clear recommendations on its management have been defined. The present paper was written to provide an overview of the risk of HBV reactivation in non-neoplastic patients treated with immunosuppressive drugs, particularly for rheumatological, gastrointestinal, dermatological and neurological diseases, and for COVID-19 patients receiving immunomodulating agents; and to discuss the potential strategies for prevention and treatment of HBVr in these settings.
format	article
author	Lorenzo Onorato Mariantonietta Pisaturo Clarissa Camaioni Pierantonio Grimaldi Alessio Vinicio Codella Federica Calò Nicola Coppola
author_facet	Lorenzo Onorato Mariantonietta Pisaturo Clarissa Camaioni Pierantonio Grimaldi Alessio Vinicio Codella Federica Calò Nicola Coppola
author_sort	Lorenzo Onorato
title	Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases
title_short	Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases
title_full	Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases
title_fullStr	Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases
title_full_unstemmed	Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases
title_sort	risk and prevention of hepatitis b virus reactivation during immunosuppression for non-oncological diseases
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/ba33ec8552d54797824e2c1386376070
work_keys_str_mv	AT lorenzoonorato riskandpreventionofhepatitisbvirusreactivationduringimmunosuppressionfornononcologicaldiseases AT mariantoniettapisaturo riskandpreventionofhepatitisbvirusreactivationduringimmunosuppressionfornononcologicaldiseases AT clarissacamaioni riskandpreventionofhepatitisbvirusreactivationduringimmunosuppressionfornononcologicaldiseases AT pierantoniogrimaldi riskandpreventionofhepatitisbvirusreactivationduringimmunosuppressionfornononcologicaldiseases AT alessioviniciocodella riskandpreventionofhepatitisbvirusreactivationduringimmunosuppressionfornononcologicaldiseases AT federicacalo riskandpreventionofhepatitisbvirusreactivationduringimmunosuppressionfornononcologicaldiseases AT nicolacoppola riskandpreventionofhepatitisbvirusreactivationduringimmunosuppressionfornononcologicaldiseases
_version_	1718432022706257920

Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases

Ejemplares similares